

Alessandra Rossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3104359/publications.pdf>

Version: 2024-02-01

44
papers

1,306
citations

331670

21
h-index

361022

35
g-index

45
all docs

45
docs citations

45
times ranked

1801
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of solid lipid microparticles by melt-emulsification/spray-drying processes as carriers for pulmonary drug delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 156, 105588.	4.0	12
2	Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18 β -Glycyrrhetic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer. <i>Pharmaceutics</i> , 2021, 13, 1792.	4.5	28
3	Inhalable Microparticles Embedding Calcium Phosphate Nanoparticles for Heart Targeting: The Formulation Experimental Design. <i>Pharmaceutics</i> , 2021, 13, 1825.	4.5	13
4	Comparative Assessment of In Vitro and In Silico Methods for Aerodynamic Characterization of Powders for Inhalation. <i>Pharmaceutics</i> , 2021, 13, 1831.	4.5	7
5	Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats. <i>Journal of Controlled Release</i> , 2020, 323, 412-420.	9.9	21
6	Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction. <i>Drug Development and Industrial Pharmacy</i> , 2019, 45, 1664-1673.	2.0	8
7	Aerosolization Performance of Jet Nebulizers and Biopharmaceutical Aspects. <i>Pharmaceutics</i> , 2019, 11, 406.	4.5	18
8	Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease. <i>Journal of Drug Targeting</i> , 2019, 27, 984-994.	4.4	21
9	Nebulized coenzyme Q 10 nanosuspensions: A versatile approach for pulmonary antioxidant therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 113, 159-170.	4.0	23
10	Opportunity and challenges of nasal powders: Drug formulation and delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 113, 2-17.	4.0	83
11	Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 113, 18-28.	4.0	46
12	The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 113, 64-76.	4.0	45
13	Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. <i>International Journal of Pharmaceutics</i> , 2018, 548, 182-191.	5.2	27
14	Multi-kinetics and site-specific release of gabapentin and flurbiprofen from oral fixed-dose combination: in vitro release and in vivo food effect. <i>Journal of Controlled Release</i> , 2017, 262, 296-304.	9.9	10
15	In Vivo Assessment of Clobetasol Propionate-Loaded Lecithin-Chitosan Nanoparticles for Skin Delivery. <i>International Journal of Molecular Sciences</i> , 2017, 18, 32.	4.1	27
16	Overview on gastroretentive drug delivery systems for improving drug bioavailability. <i>International Journal of Pharmaceutics</i> , 2016, 510, 144-158.	5.2	194
17	Comparison of breaking tests for the characterization of the interfacial strength of bilayer tablets. <i>International Journal of Pharmaceutics</i> , 2016, 513, 709-716.	5.2	12
18	Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. <i>International Journal of Pharmaceutics</i> , 2016, 514, 229-237.	5.2	22

#	ARTICLE	IF	CITATIONS
19	Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats. <i>Journal of Controlled Release</i> , 2016, 239, 203-210.	9.9	12
20	Development and validation of a DESI-MS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study. <i>Drug Testing and Analysis</i> , 2016, 8, 208-213.	2.6	18
21	Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients. <i>International Journal of Pharmaceutics</i> , 2016, 502, 242-248.	5.2	19
22	Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 332-339.	2.0	23
23	Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 165-172.	4.3	46
24	Pierce and inhale design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs. <i>International Journal of Pharmaceutics</i> , 2015, 487, 197-204.	5.2	38
25	High shear mixing of lactose and salmeterol xinafoate dry powder blends: Biopharmaceutic and aerodynamic performances. <i>Journal of Drug Delivery Science and Technology</i> , 2015, 30, 443-449.	3.0	13
26	Spray dried amikacin powder for inhalation in cystic fibrosis patients: A quality by design approach for product construction. <i>International Journal of Pharmaceutics</i> , 2014, 471, 507-515.	5.2	44
27	Pure insulin highly respirable powders for inhalation. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 51, 110-117.	4.0	30
28	Agglomerated Oral Dosage Forms of Artemisinin/ β -Cyclodextrin Spray-Dried Primary Microparticles Showing Increased Dissolution Rate and Bioavailability. <i>AAPS PharmSciTech</i> , 2013, 14, 911-918.	3.3	22
29	Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration. <i>International Journal of Pharmaceutics</i> , 2013, 451, 50-56.	5.2	4
30	Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: Loading, enzyme-trigger release and cell uptake. <i>Journal of Controlled Release</i> , 2013, 167, 276-283.	9.9	55
31	Innovative Technologies for Oral Drug Delivery. <i>Current Drug Delivery</i> , 2013, 10, 4-8.	1.6	1
32	Chlorhexidine Salt-Loaded Polyurethane Orthodontic Chains: In Vitro Release and Antibacterial Activity Studies. <i>AAPS PharmSciTech</i> , 2012, 13, 1446-1450.	3.3	14
33	Particles and powders: Tools of innovation for non-invasive drug administration. <i>Journal of Controlled Release</i> , 2012, 161, 693-702.	9.9	59
34	Layered lipid microcapsules for mesalazine delayed-release in children. <i>International Journal of Pharmaceutics</i> , 2011, 421, 293-300.	5.2	20
35	Characterization of a polyurethane-based controlled release system for local delivery of chlorhexidine diacetate. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 74, 255-264.	4.3	67
36	Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazole-loaded microparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 74, 275-280.	4.3	13

#	ARTICLE	IF	CITATIONS
37	Therapeutic Paint of Cidofovir/Sucralfate Gel Combination Topically Administered by Spraying for Treatment of orf virus Infections. AAPS Journal, 2009, 11, 242-249.	4.4	18
38	Agglomerates Containing Pantoprazole Microparticles: Modulating the Drug Release. AAPS PharmSciTech, 2009, 10, 335-345.	3.3	12
39	Hesperidin Gastroresistant Microparticles by Spray-Drying: Preparation, Characterization, and Dissolution Profiles. AAPS PharmSciTech, 2009, 10, 391-401.	3.3	51
40	Quercetin microspheres by solvent evaporation: Preparation, characterization and release behavior. Journal of Applied Polymer Science, 2008, 109, 2994-3001.	2.6	23
41	Non-phospholipid vesicles as carriers for peptides and proteins: Production, characterization and stability studies. International Journal of Pharmaceutics, 2007, 339, 52-60.	5.2	26
42	Primary Microparticles and Agglomerates of Morphine for Nasal Insufflation. Journal of Pharmaceutical Sciences, 2006, 95, 2553-2561.	3.3	35
43	Polymorphism of rac-5,6-diisobutyryloxy-2-methylamino-1,2,3,4-tetrahydro-naphthalene hydrochloride (CHF 1035). I. Thermal, spectroscopic, and X-ray diffraction properties. Journal of Pharmaceutical Sciences, 2001, 90, 1154-1163.	3.3	12
44	New Farnesane Sesquiterpenes from Lactarius porninsis. Journal of Natural Products, 1993, 56, 1948-1953.	3.0	14